nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—C-reactive protein increased—Varenicline—nicotine dependence	0.0486	0.0754	CcSEcCtD
Bortezomib—Change of bowel habit—Varenicline—nicotine dependence	0.0351	0.0545	CcSEcCtD
Bortezomib—Tongue coated—Varenicline—nicotine dependence	0.0299	0.0464	CcSEcCtD
Bortezomib—CTSG—cardiovascular system—nicotine dependence	0.0244	0.102	CbGeAlD
Bortezomib—PSMA1—cardiovascular system—nicotine dependence	0.0234	0.0975	CbGeAlD
Bortezomib—Upper-airway cough syndrome—Varenicline—nicotine dependence	0.0222	0.0344	CcSEcCtD
Bortezomib—PSMD2—cardiovascular system—nicotine dependence	0.0174	0.0725	CbGeAlD
Bortezomib—Pleurisy—Varenicline—nicotine dependence	0.0166	0.0257	CcSEcCtD
Bortezomib—PSMD1—midbrain—nicotine dependence	0.0154	0.0639	CbGeAlD
Bortezomib—Restless legs syndrome—Varenicline—nicotine dependence	0.0142	0.022	CcSEcCtD
Bortezomib—Abnormal faeces—Varenicline—nicotine dependence	0.0142	0.022	CcSEcCtD
Bortezomib—PSMD2—midbrain—nicotine dependence	0.0136	0.0566	CbGeAlD
Bortezomib—Joint stiffness—Varenicline—nicotine dependence	0.0134	0.0208	CcSEcCtD
Bortezomib—PSMB1—cardiovascular system—nicotine dependence	0.0134	0.0557	CbGeAlD
Bortezomib—PSMB2—cardiovascular system—nicotine dependence	0.0131	0.0543	CbGeAlD
Bortezomib—PSMB5—midbrain—nicotine dependence	0.012	0.0497	CbGeAlD
Bortezomib—PSMA1—brain—nicotine dependence	0.0115	0.0479	CbGeAlD
Bortezomib—Respiratory tract congestion—Varenicline—nicotine dependence	0.0111	0.0172	CcSEcCtD
Bortezomib—PSMB1—midbrain—nicotine dependence	0.0104	0.0435	CbGeAlD
Bortezomib—PSMB2—midbrain—nicotine dependence	0.0102	0.0424	CbGeAlD
Bortezomib—Drug hypersensitivity—Varenicline—nicotine dependence	0.01	0.0156	CcSEcCtD
Bortezomib—PSMD1—brain—nicotine dependence	0.00966	0.0402	CbGeAlD
Bortezomib—SLC31A1—midbrain—nicotine dependence	0.00883	0.0367	CbGeAlD
Bortezomib—Pancreatitis acute—Varenicline—nicotine dependence	0.00877	0.0136	CcSEcCtD
Bortezomib—PSMD2—brain—nicotine dependence	0.00855	0.0356	CbGeAlD
Bortezomib—PSMB8—brain—nicotine dependence	0.0085	0.0354	CbGeAlD
Bortezomib—Throat irritation—Varenicline—nicotine dependence	0.00802	0.0125	CcSEcCtD
Bortezomib—Transient ischaemic attack—Varenicline—nicotine dependence	0.00802	0.0125	CcSEcCtD
Bortezomib—PSMB5—brain—nicotine dependence	0.00751	0.0312	CbGeAlD
Bortezomib—Night sweats—Varenicline—nicotine dependence	0.0075	0.0116	CcSEcCtD
Bortezomib—Urine analysis abnormal—Varenicline—nicotine dependence	0.00688	0.0107	CcSEcCtD
Bortezomib—Platelet count decreased—Varenicline—nicotine dependence	0.0068	0.0106	CcSEcCtD
Bortezomib—PSMB1—brain—nicotine dependence	0.00656	0.0273	CbGeAlD
Bortezomib—Psoriasis—Varenicline—nicotine dependence	0.00644	0.01	CcSEcCtD
Bortezomib—PSMB2—brain—nicotine dependence	0.00641	0.0266	CbGeAlD
Bortezomib—Parosmia—Varenicline—nicotine dependence	0.00624	0.00969	CcSEcCtD
Bortezomib—Cyst—Varenicline—nicotine dependence	0.00605	0.0094	CcSEcCtD
Bortezomib—Intestinal obstruction—Varenicline—nicotine dependence	0.00594	0.00922	CcSEcCtD
Bortezomib—Haematemesis—Varenicline—nicotine dependence	0.00582	0.00905	CcSEcCtD
Bortezomib—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00577	0.0499	CbGpPWpGaD
Bortezomib—Suicidal ideation—Varenicline—nicotine dependence	0.00577	0.00896	CcSEcCtD
Bortezomib—SLC31A1—brain—nicotine dependence	0.00555	0.0231	CbGeAlD
Bortezomib—Scotoma—Varenicline—nicotine dependence	0.00533	0.00828	CcSEcCtD
Bortezomib—Fungal infection—Varenicline—nicotine dependence	0.00524	0.00814	CcSEcCtD
Bortezomib—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00515	0.0445	CbGpPWpGaD
Bortezomib—Nephrolithiasis—Varenicline—nicotine dependence	0.00503	0.00782	CcSEcCtD
Bortezomib—Rhinorrhoea—Varenicline—nicotine dependence	0.005	0.00776	CcSEcCtD
Bortezomib—Dysphonia—Varenicline—nicotine dependence	0.00492	0.00764	CcSEcCtD
Bortezomib—Endocrine disorder—Varenicline—nicotine dependence	0.00488	0.00758	CcSEcCtD
Bortezomib—Acne—Varenicline—nicotine dependence	0.00481	0.00747	CcSEcCtD
Bortezomib—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00474	0.0409	CbGpPWpGaD
Bortezomib—Eye irritation—Varenicline—nicotine dependence	0.00474	0.00736	CcSEcCtD
Bortezomib—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0047	0.0406	CbGpPWpGaD
Bortezomib—Disturbance in attention—Varenicline—nicotine dependence	0.00467	0.00726	CcSEcCtD
Bortezomib—Tenderness—Varenicline—nicotine dependence	0.00464	0.0072	CcSEcCtD
Bortezomib—Chest discomfort—Varenicline—nicotine dependence	0.00457	0.0071	CcSEcCtD
Bortezomib—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00448	0.00696	CcSEcCtD
Bortezomib—Viral infection—Varenicline—nicotine dependence	0.00448	0.00696	CcSEcCtD
Bortezomib—Lacrimation increased—Varenicline—nicotine dependence	0.00439	0.00682	CcSEcCtD
Bortezomib—Leukocytosis—Varenicline—nicotine dependence	0.00431	0.00669	CcSEcCtD
Bortezomib—Dysarthria—Varenicline—nicotine dependence	0.00428	0.00665	CcSEcCtD
Bortezomib—Musculoskeletal pain—Varenicline—nicotine dependence	0.0041	0.00636	CcSEcCtD
Bortezomib—Pulmonary embolism—Varenicline—nicotine dependence	0.00405	0.00629	CcSEcCtD
Bortezomib—Hyperkalaemia—Varenicline—nicotine dependence	0.00398	0.00618	CcSEcCtD
Bortezomib—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.0039	0.0337	CbGpPWpGaD
Bortezomib—Photophobia—Varenicline—nicotine dependence	0.0038	0.0059	CcSEcCtD
Bortezomib—Dry eye—Varenicline—nicotine dependence	0.00374	0.00581	CcSEcCtD
Bortezomib—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0037	0.0319	CbGpPWpGaD
Bortezomib—Oesophagitis—Varenicline—nicotine dependence	0.0037	0.00574	CcSEcCtD
Bortezomib—CYP2C9—cardiovascular system—nicotine dependence	0.00369	0.0154	CbGeAlD
Bortezomib—Mouth ulceration—Varenicline—nicotine dependence	0.00366	0.00568	CcSEcCtD
Bortezomib—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00358	0.0309	CbGpPWpGaD
Bortezomib—Lymphadenopathy—Varenicline—nicotine dependence	0.00344	0.00535	CcSEcCtD
Bortezomib—Sleep disorder—Varenicline—nicotine dependence	0.00339	0.00527	CcSEcCtD
Bortezomib—Diabetes mellitus—Varenicline—nicotine dependence	0.00338	0.00525	CcSEcCtD
Bortezomib—PTGS1—cardiovascular system—nicotine dependence	0.00337	0.014	CbGeAlD
Bortezomib—Deafness—Varenicline—nicotine dependence	0.00328	0.0051	CcSEcCtD
Bortezomib—Eye pain—Varenicline—nicotine dependence	0.00325	0.00505	CcSEcCtD
Bortezomib—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00319	0.0276	CbGpPWpGaD
Bortezomib—Renal failure acute—Varenicline—nicotine dependence	0.00318	0.00494	CcSEcCtD
Bortezomib—Libido decreased—Varenicline—nicotine dependence	0.00317	0.00492	CcSEcCtD
Bortezomib—Increased appetite—Varenicline—nicotine dependence	0.00313	0.00486	CcSEcCtD
Bortezomib—Amnesia—Varenicline—nicotine dependence	0.00313	0.00486	CcSEcCtD
Bortezomib—Atrial fibrillation—Varenicline—nicotine dependence	0.0031	0.00481	CcSEcCtD
Bortezomib—Thirst—Varenicline—nicotine dependence	0.00309	0.00479	CcSEcCtD
Bortezomib—Arthritis—Varenicline—nicotine dependence	0.00302	0.00469	CcSEcCtD
Bortezomib—Lethargy—Varenicline—nicotine dependence	0.003	0.00466	CcSEcCtD
Bortezomib—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00294	0.0254	CbGpPWpGaD
Bortezomib—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00294	0.00456	CcSEcCtD
Bortezomib—Osteoarthritis—Varenicline—nicotine dependence	0.00294	0.00456	CcSEcCtD
Bortezomib—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00291	0.00453	CcSEcCtD
Bortezomib—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00291	0.0252	CbGpPWpGaD
Bortezomib—Migraine—Varenicline—nicotine dependence	0.00289	0.00449	CcSEcCtD
Bortezomib—Psychotic disorder—Varenicline—nicotine dependence	0.00287	0.00446	CcSEcCtD
Bortezomib—Irritability—Varenicline—nicotine dependence	0.0028	0.00435	CcSEcCtD
Bortezomib—Urinary retention—Varenicline—nicotine dependence	0.00279	0.00434	CcSEcCtD
Bortezomib—Dry skin—Varenicline—nicotine dependence	0.00269	0.00418	CcSEcCtD
Bortezomib—Abdominal pain upper—Varenicline—nicotine dependence	0.00268	0.00417	CcSEcCtD
Bortezomib—Hypokalaemia—Varenicline—nicotine dependence	0.00267	0.00415	CcSEcCtD
Bortezomib—Breast disorder—Varenicline—nicotine dependence	0.00265	0.00412	CcSEcCtD
Bortezomib—Cramp muscle—Varenicline—nicotine dependence	0.00265	0.00411	CcSEcCtD
Bortezomib—Nasopharyngitis—Varenicline—nicotine dependence	0.00263	0.00408	CcSEcCtD
Bortezomib—Gastritis—Varenicline—nicotine dependence	0.0026	0.00404	CcSEcCtD
Bortezomib—Abdominal distension—Varenicline—nicotine dependence	0.00256	0.00397	CcSEcCtD
Bortezomib—Dysphagia—Varenicline—nicotine dependence	0.00254	0.00394	CcSEcCtD
Bortezomib—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00249	0.0215	CbGpPWpGaD
Bortezomib—Angina pectoris—Varenicline—nicotine dependence	0.00247	0.00384	CcSEcCtD
Bortezomib—Bronchitis—Varenicline—nicotine dependence	0.00244	0.00379	CcSEcCtD
Bortezomib—Abdominal discomfort—Varenicline—nicotine dependence	0.00243	0.00378	CcSEcCtD
Bortezomib—Pollakiuria—Varenicline—nicotine dependence	0.00235	0.00364	CcSEcCtD
Bortezomib—Erectile dysfunction—Varenicline—nicotine dependence	0.00234	0.00363	CcSEcCtD
Bortezomib—Photosensitivity reaction—Varenicline—nicotine dependence	0.00232	0.0036	CcSEcCtD
Bortezomib—Weight increased—Varenicline—nicotine dependence	0.00231	0.00359	CcSEcCtD
Bortezomib—Hyperglycaemia—Varenicline—nicotine dependence	0.00229	0.00356	CcSEcCtD
Bortezomib—Infestation NOS—Varenicline—nicotine dependence	0.00226	0.00352	CcSEcCtD
Bortezomib—Infestation—Varenicline—nicotine dependence	0.00226	0.00352	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00224	0.00349	CcSEcCtD
Bortezomib—Acute coronary syndrome—Varenicline—nicotine dependence	0.00223	0.00347	CcSEcCtD
Bortezomib—Myocardial infarction—Varenicline—nicotine dependence	0.00222	0.00345	CcSEcCtD
Bortezomib—Stomatitis—Varenicline—nicotine dependence	0.00221	0.00343	CcSEcCtD
Bortezomib—Conjunctivitis—Varenicline—nicotine dependence	0.0022	0.00342	CcSEcCtD
Bortezomib—Hepatobiliary disease—Varenicline—nicotine dependence	0.00214	0.00333	CcSEcCtD
Bortezomib—Epistaxis—Varenicline—nicotine dependence	0.00214	0.00332	CcSEcCtD
Bortezomib—Sinusitis—Varenicline—nicotine dependence	0.00212	0.0033	CcSEcCtD
Bortezomib—Bradycardia—Varenicline—nicotine dependence	0.00207	0.00321	CcSEcCtD
Bortezomib—CYP2C8—brain—nicotine dependence	0.00204	0.00849	CbGeAlD
Bortezomib—Hypoaesthesia—Varenicline—nicotine dependence	0.00202	0.00314	CcSEcCtD
Bortezomib—Hallucination—Varenicline—nicotine dependence	0.00202	0.00314	CcSEcCtD
Bortezomib—Urinary tract disorder—Varenicline—nicotine dependence	0.00201	0.00312	CcSEcCtD
Bortezomib—Oedema peripheral—Varenicline—nicotine dependence	0.002	0.00311	CcSEcCtD
Bortezomib—Connective tissue disorder—Varenicline—nicotine dependence	0.002	0.0031	CcSEcCtD
Bortezomib—Urethral disorder—Varenicline—nicotine dependence	0.00199	0.00309	CcSEcCtD
Bortezomib—Visual impairment—Varenicline—nicotine dependence	0.00196	0.00304	CcSEcCtD
Bortezomib—Erythema multiforme—Varenicline—nicotine dependence	0.00192	0.00298	CcSEcCtD
Bortezomib—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00192	0.0166	CbGpPWpGaD
Bortezomib—Eye disorder—Varenicline—nicotine dependence	0.0019	0.00295	CcSEcCtD
Bortezomib—Tinnitus—Varenicline—nicotine dependence	0.00189	0.00294	CcSEcCtD
Bortezomib—Cardiac disorder—Varenicline—nicotine dependence	0.00189	0.00293	CcSEcCtD
Bortezomib—CYP1A1—brain—nicotine dependence	0.00188	0.00784	CbGeAlD
Bortezomib—PTGS1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00186	0.0161	CbGpPWpGaD
Bortezomib—Angiopathy—Varenicline—nicotine dependence	0.00184	0.00286	CcSEcCtD
Bortezomib—Immune system disorder—Varenicline—nicotine dependence	0.00184	0.00285	CcSEcCtD
Bortezomib—Mediastinal disorder—Varenicline—nicotine dependence	0.00183	0.00284	CcSEcCtD
Bortezomib—Chills—Varenicline—nicotine dependence	0.00182	0.00283	CcSEcCtD
Bortezomib—Arrhythmia—Varenicline—nicotine dependence	0.00182	0.00282	CcSEcCtD
Bortezomib—Mental disorder—Varenicline—nicotine dependence	0.00178	0.00277	CcSEcCtD
Bortezomib—Malnutrition—Varenicline—nicotine dependence	0.00177	0.00275	CcSEcCtD
Bortezomib—Erythema—Varenicline—nicotine dependence	0.00177	0.00275	CcSEcCtD
Bortezomib—Flatulence—Varenicline—nicotine dependence	0.00174	0.00271	CcSEcCtD
Bortezomib—Dysgeusia—Varenicline—nicotine dependence	0.00173	0.00269	CcSEcCtD
Bortezomib—Back pain—Varenicline—nicotine dependence	0.00171	0.00266	CcSEcCtD
Bortezomib—Muscle spasms—Varenicline—nicotine dependence	0.0017	0.00264	CcSEcCtD
Bortezomib—Vision blurred—Varenicline—nicotine dependence	0.00167	0.00259	CcSEcCtD
Bortezomib—Tremor—Varenicline—nicotine dependence	0.00166	0.00257	CcSEcCtD
Bortezomib—PTGS1—brain—nicotine dependence	0.00166	0.00688	CbGeAlD
Bortezomib—Ill-defined disorder—Varenicline—nicotine dependence	0.00164	0.00255	CcSEcCtD
Bortezomib—Anaemia—Varenicline—nicotine dependence	0.00164	0.00254	CcSEcCtD
Bortezomib—Agitation—Varenicline—nicotine dependence	0.00163	0.00253	CcSEcCtD
Bortezomib—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00162	0.014	CbGpPWpGaD
Bortezomib—Angioedema—Varenicline—nicotine dependence	0.00162	0.00251	CcSEcCtD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00161	0.0139	CbGpPWpGaD
Bortezomib—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0016	0.0138	CbGpPWpGaD
Bortezomib—Malaise—Varenicline—nicotine dependence	0.0016	0.00248	CcSEcCtD
Bortezomib—Vertigo—Varenicline—nicotine dependence	0.00159	0.00247	CcSEcCtD
Bortezomib—Syncope—Varenicline—nicotine dependence	0.00159	0.00246	CcSEcCtD
Bortezomib—Palpitations—Varenicline—nicotine dependence	0.00156	0.00243	CcSEcCtD
Bortezomib—Loss of consciousness—Varenicline—nicotine dependence	0.00155	0.00242	CcSEcCtD
Bortezomib—Cough—Varenicline—nicotine dependence	0.00154	0.0024	CcSEcCtD
Bortezomib—Convulsion—Varenicline—nicotine dependence	0.00153	0.00238	CcSEcCtD
Bortezomib—Hypertension—Varenicline—nicotine dependence	0.00153	0.00237	CcSEcCtD
Bortezomib—Myalgia—Varenicline—nicotine dependence	0.00151	0.00234	CcSEcCtD
Bortezomib—Chest pain—Varenicline—nicotine dependence	0.00151	0.00234	CcSEcCtD
Bortezomib—Arthralgia—Varenicline—nicotine dependence	0.00151	0.00234	CcSEcCtD
Bortezomib—Anxiety—Varenicline—nicotine dependence	0.0015	0.00233	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.0015	0.00232	CcSEcCtD
Bortezomib—Discomfort—Varenicline—nicotine dependence	0.00149	0.00231	CcSEcCtD
Bortezomib—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00149	0.0128	CbGpPWpGaD
Bortezomib—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00147	0.0127	CbGpPWpGaD
Bortezomib—Oedema—Varenicline—nicotine dependence	0.00144	0.00224	CcSEcCtD
Bortezomib—Infection—Varenicline—nicotine dependence	0.00143	0.00223	CcSEcCtD
Bortezomib—Shock—Varenicline—nicotine dependence	0.00142	0.00221	CcSEcCtD
Bortezomib—Nervous system disorder—Varenicline—nicotine dependence	0.00142	0.0022	CcSEcCtD
Bortezomib—Thrombocytopenia—Varenicline—nicotine dependence	0.00141	0.0022	CcSEcCtD
Bortezomib—Tachycardia—Varenicline—nicotine dependence	0.00141	0.00219	CcSEcCtD
Bortezomib—Skin disorder—Varenicline—nicotine dependence	0.0014	0.00218	CcSEcCtD
Bortezomib—Hyperhidrosis—Varenicline—nicotine dependence	0.0014	0.00217	CcSEcCtD
Bortezomib—Anorexia—Varenicline—nicotine dependence	0.00138	0.00214	CcSEcCtD
Bortezomib—CYP2D6—brain—nicotine dependence	0.00136	0.00566	CbGeAlD
Bortezomib—Hypotension—Varenicline—nicotine dependence	0.00135	0.0021	CcSEcCtD
Bortezomib—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00133	0.0115	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00132	0.00204	CcSEcCtD
Bortezomib—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00131	0.0113	CbGpPWpGaD
Bortezomib—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00131	0.0113	CbGpPWpGaD
Bortezomib—Insomnia—Varenicline—nicotine dependence	0.00131	0.00203	CcSEcCtD
Bortezomib—Dyspnoea—Varenicline—nicotine dependence	0.00129	0.002	CcSEcCtD
Bortezomib—Dyspepsia—Varenicline—nicotine dependence	0.00127	0.00197	CcSEcCtD
Bortezomib—Decreased appetite—Varenicline—nicotine dependence	0.00126	0.00195	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00125	0.00194	CcSEcCtD
Bortezomib—Fatigue—Varenicline—nicotine dependence	0.00124	0.00193	CcSEcCtD
Bortezomib—Constipation—Varenicline—nicotine dependence	0.00123	0.00192	CcSEcCtD
Bortezomib—Pain—Varenicline—nicotine dependence	0.00123	0.00192	CcSEcCtD
Bortezomib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00122	0.0105	CbGpPWpGaD
Bortezomib—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00121	0.0104	CbGpPWpGaD
Bortezomib—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0012	0.0104	CbGpPWpGaD
Bortezomib—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0012	0.0104	CbGpPWpGaD
Bortezomib—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00119	0.0103	CbGpPWpGaD
Bortezomib—Feeling abnormal—Varenicline—nicotine dependence	0.00119	0.00185	CcSEcCtD
Bortezomib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00118	0.00183	CcSEcCtD
Bortezomib—Urticaria—Varenicline—nicotine dependence	0.00115	0.00178	CcSEcCtD
Bortezomib—Body temperature increased—Varenicline—nicotine dependence	0.00114	0.00177	CcSEcCtD
Bortezomib—Abdominal pain—Varenicline—nicotine dependence	0.00114	0.00177	CcSEcCtD
Bortezomib—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00108	0.00929	CbGpPWpGaD
Bortezomib—Hypersensitivity—Varenicline—nicotine dependence	0.00106	0.00165	CcSEcCtD
Bortezomib—Asthenia—Varenicline—nicotine dependence	0.00104	0.00161	CcSEcCtD
Bortezomib—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00103	0.00893	CbGpPWpGaD
Bortezomib—Pruritus—Varenicline—nicotine dependence	0.00102	0.00159	CcSEcCtD
Bortezomib—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00102	0.00881	CbGpPWpGaD
Bortezomib—PTGS1—Biological oxidations—CYP2A7—nicotine dependence	0.000991	0.00856	CbGpPWpGaD
Bortezomib—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000989	0.00854	CbGpPWpGaD
Bortezomib—Diarrhoea—Varenicline—nicotine dependence	0.000988	0.00153	CcSEcCtD
Bortezomib—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00098	0.00847	CbGpPWpGaD
Bortezomib—Dizziness—Varenicline—nicotine dependence	0.000955	0.00148	CcSEcCtD
Bortezomib—Vomiting—Varenicline—nicotine dependence	0.000918	0.00143	CcSEcCtD
Bortezomib—Rash—Varenicline—nicotine dependence	0.00091	0.00141	CcSEcCtD
Bortezomib—Dermatitis—Varenicline—nicotine dependence	0.00091	0.00141	CcSEcCtD
Bortezomib—Headache—Varenicline—nicotine dependence	0.000904	0.0014	CcSEcCtD
Bortezomib—Nausea—Varenicline—nicotine dependence	0.000858	0.00133	CcSEcCtD
Bortezomib—PSMA1—Gene Expression—CCAR1—nicotine dependence	0.000853	0.00737	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—CCAR1—nicotine dependence	0.000849	0.00734	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—CCAR1—nicotine dependence	0.000845	0.0073	CbGpPWpGaD
Bortezomib—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000838	0.00724	CbGpPWpGaD
Bortezomib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000798	0.00689	CbGpPWpGaD
Bortezomib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000787	0.0068	CbGpPWpGaD
Bortezomib—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00074	0.0064	CbGpPWpGaD
Bortezomib—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.000698	0.00603	CbGpPWpGaD
Bortezomib—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000688	0.00595	CbGpPWpGaD
Bortezomib—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000679	0.00586	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—CCAR1—nicotine dependence	0.000647	0.00559	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—CCAR1—nicotine dependence	0.000647	0.00559	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—CCAR1—nicotine dependence	0.000647	0.00559	CbGpPWpGaD
Bortezomib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000647	0.00558	CbGpPWpGaD
Bortezomib—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00064	0.00553	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—CCAR1—nicotine dependence	0.000638	0.00551	CbGpPWpGaD
Bortezomib—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000631	0.00545	CbGpPWpGaD
Bortezomib—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000606	0.00523	CbGpPWpGaD
Bortezomib—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000571	0.00493	CbGpPWpGaD
Bortezomib—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000563	0.00487	CbGpPWpGaD
Bortezomib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000557	0.00481	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TAS2R16—nicotine dependence	0.000555	0.00479	CbGpPWpGaD
Bortezomib—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000552	0.00477	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TAS2R16—nicotine dependence	0.000552	0.00477	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TAS2R16—nicotine dependence	0.00055	0.00475	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKR1B10—nicotine dependence	0.000549	0.00474	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKR1B10—nicotine dependence	0.000547	0.00472	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKR1B10—nicotine dependence	0.000544	0.0047	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000525	0.00454	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000521	0.0045	CbGpPWpGaD
Bortezomib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000518	0.00447	CbGpPWpGaD
Bortezomib—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000514	0.00444	CbGpPWpGaD
Bortezomib—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000472	0.00408	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000445	0.00384	CbGpPWpGaD
Bortezomib—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000439	0.00379	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FGD1—nicotine dependence	0.000435	0.00376	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FGD1—nicotine dependence	0.000433	0.00374	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FGD1—nicotine dependence	0.000431	0.00372	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—CYP2A7—nicotine dependence	0.000428	0.00369	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—CYP2A7—nicotine dependence	0.000426	0.00368	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—CYP2A7—nicotine dependence	0.000424	0.00366	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TAS2R16—nicotine dependence	0.000421	0.00363	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TAS2R16—nicotine dependence	0.000421	0.00363	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TAS2R16—nicotine dependence	0.000421	0.00363	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—WASF2—nicotine dependence	0.000419	0.00362	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—WASF2—nicotine dependence	0.000417	0.0036	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKR1B10—nicotine dependence	0.000416	0.00359	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKR1B10—nicotine dependence	0.000416	0.00359	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKR1B10—nicotine dependence	0.000416	0.00359	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—WASF2—nicotine dependence	0.000415	0.00359	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TAS2R16—nicotine dependence	0.000415	0.00358	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKR1B10—nicotine dependence	0.00041	0.00354	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—WASF1—nicotine dependence	0.000402	0.00347	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—WASF1—nicotine dependence	0.0004	0.00345	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—WASF1—nicotine dependence	0.000398	0.00344	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKR1B10—nicotine dependence	0.000385	0.00332	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKR1B10—nicotine dependence	0.000383	0.00331	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKR1B10—nicotine dependence	0.000381	0.00329	CbGpPWpGaD
Bortezomib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000364	0.00315	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000343	0.00297	CbGpPWpGaD
Bortezomib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000339	0.00293	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FGD1—nicotine dependence	0.00033	0.00285	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FGD1—nicotine dependence	0.00033	0.00285	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FGD1—nicotine dependence	0.00033	0.00285	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FGD1—nicotine dependence	0.000325	0.00281	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CYP2A7—nicotine dependence	0.000324	0.0028	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CYP2A7—nicotine dependence	0.000324	0.0028	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CYP2A7—nicotine dependence	0.000324	0.0028	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CYP2A7—nicotine dependence	0.000319	0.00276	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—WASF2—nicotine dependence	0.000318	0.00274	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—WASF2—nicotine dependence	0.000318	0.00274	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—WASF2—nicotine dependence	0.000318	0.00274	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—WASF2—nicotine dependence	0.000313	0.0027	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—WASF1—nicotine dependence	0.000305	0.00263	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—WASF1—nicotine dependence	0.000305	0.00263	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—WASF1—nicotine dependence	0.000305	0.00263	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—WASF1—nicotine dependence	0.0003	0.00259	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKR1B10—nicotine dependence	0.000291	0.00252	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKR1B10—nicotine dependence	0.000291	0.00252	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKR1B10—nicotine dependence	0.000291	0.00252	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKR1B10—nicotine dependence	0.000287	0.00248	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—WASF2—nicotine dependence	0.000271	0.00234	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—WASF2—nicotine dependence	0.00027	0.00233	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—WASF2—nicotine dependence	0.000268	0.00232	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—WASF1—nicotine dependence	0.00026	0.00224	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—WASF1—nicotine dependence	0.000259	0.00223	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—WASF1—nicotine dependence	0.000257	0.00222	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—OPRM1—nicotine dependence	0.000234	0.00202	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—OPRM1—nicotine dependence	0.000233	0.00201	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—OPRM1—nicotine dependence	0.000232	0.002	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—WASF2—nicotine dependence	0.000205	0.00177	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—WASF2—nicotine dependence	0.000205	0.00177	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—WASF2—nicotine dependence	0.000205	0.00177	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—WASF2—nicotine dependence	0.000202	0.00175	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—WASF1—nicotine dependence	0.000197	0.0017	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—WASF1—nicotine dependence	0.000197	0.0017	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—WASF1—nicotine dependence	0.000197	0.0017	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—WASF1—nicotine dependence	0.000194	0.00168	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—OPRM1—nicotine dependence	0.000177	0.00153	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—OPRM1—nicotine dependence	0.000177	0.00153	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—OPRM1—nicotine dependence	0.000177	0.00153	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—OPRM1—nicotine dependence	0.000175	0.00151	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP2A7—nicotine dependence	0.000169	0.00146	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—DRD2—nicotine dependence	0.000169	0.00146	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—DRD2—nicotine dependence	0.000168	0.00145	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—DRD2—nicotine dependence	0.000168	0.00145	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—DRD2—nicotine dependence	0.000128	0.00111	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—DRD2—nicotine dependence	0.000128	0.00111	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—DRD2—nicotine dependence	0.000128	0.00111	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—DRD2—nicotine dependence	0.000126	0.00109	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000119	0.00103	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000109	0.000945	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP2A7—nicotine dependence	9.77e-05	0.000844	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	8.98e-05	0.000776	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2A7—nicotine dependence	8.91e-05	0.000769	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2A7—nicotine dependence	7.61e-05	0.000657	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	5.87e-05	0.000507	CbGpPWpGaD
